Automated liquid culture of mycobacteria with phenotypic drug susceptibility testing — the reference pathway for confirming viable TB and defining resistance.
Molecular tests are fast but cannot prove viability or measure the full resistance phenotype. Culture recovers living organisms — the only route to complete drug susceptibility testing and to isolates for further characterisation.
Paucibacillary, smear-negative and extrapulmonary TB are frequently missed by microscopy and may challenge molecular tests. Liquid culture is the most sensitive routine method for recovering M. tuberculosis.
MGIT culture shortens time-to-detection versus solid media and provides the isolate needed for phenotypic DST against first- and second-line drugs — the reference basis for MDR/XDR-TB regimen design.
Universal sterile container · Cap: White
Additive: None
Volume: 10–30 mL capacity
Collect aseptically; label immediately.
Sterile container · Cap: White
Additive: None
Volume: 3–5 mL
Collect early-morning deep-cough sample for mycobacterial testing.
Validated target list: data to be updated. Please contact ID Labs for the current configuration.
| Characteristic | Value | Source |
|---|---|---|
| Analytical / clinical performance | Performance characteristics: please contact ID Labs — data to be updated. | ID Labs Validated Performance |
World Health Organization
WHO Guidelines · 2021 (updated)
WHO recommendations on rapid molecular diagnostics for TB, including Xpert MTB/RIF and line probe assays, and their place within diagnostic algorithms. These are international guidelines; they do not constitute ID Labs validated performance data.
World Health Organization · 2018
Curated peer-reviewed / authoritative reference. Open the source link for the full text.
BMC Infectious Diseases · 2012
Curated peer-reviewed / authoritative reference. Open the source link for the full text.
Rapid automated molecular detection of M. tuberculosis complex and rifampicin resistance directly from sputum and other specimens.
Molecular detection of M. tuberculosis complex with first-line (isoniazid, rifampicin) and second-line drug-resistance mutations by reverse hybridisation.
Panel configuration, specimen logistics and turnaround details on request.
Information on this page is educational and does not replace professional clinical judgment. Performance values are labelled by source (ID Labs Specification / ID Labs Validated Performance / Manufacturer Specification / Published Scientific Evidence). Molecular results must be correlated clinically and, where appropriate, confirmed by culture and phenotypic susceptibility testing.
